Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride

NCT02312960 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02312960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02312960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride
Lead sponsor
Bayer
Phase
Phase 4
Overall status
Completed
Start date
December 18, 2014
Completion date
January 31, 2024
Enrollment
255 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastasis / bone and bones